References
- Andresen, E. M., J. A. Malmgren, W. B. Carter, and D. L. Patrick. 1994. Screening for depression in well older adults: Evaluation of a short form of the CES-D. American Journal of Preventive Medicine 10 (2):77–84. doi:https://doi.org/10.1016/S0749-3797(18)30622-6.
- Arditte, K. A., D. Çek, A. M. Shaw, and K. R. Timpano. 2016. The importance of assessing clinical phenomena in mechanical Turk research. Psychological Assessment 28 (6):684. doi:https://doi.org/10.1037/pas0000217.
- Becker, J. 2015. Regarding the transpersonal nature of ketamine therapy: An approach to the work. International Journal of Transpersonal Studies 33 (2):151-159. https://doi.org/http://dx.doi.org/10.24972/ijts.2014.33.2.151
- Beshai, S., L. M. Watson, T. J. Meadows, and J. N. Soucy. 2019. Perceptions of cognitive-behavioral therapy and antidepressant medication for depression after brief psychoeducation: Examining shifts in attitudes. Behavior Therapy 50 (5):851–63. doi:https://doi.org/10.1016/j.beth.2019.01.001.
- Boschloo, L., E. Bekhuis, E. S. Weitz, M. Reijnders, R. J. DeRubeis, S. Dimidjian, D. L. Dunner, B. W. Dunlop, U. Hegerl, S. D. Hollon, et al. 2019. The symptom–specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: Results from an individual patient data meta–analysis. World Psychiatry 18 (2):183–91. doi:https://doi.org/10.1002/wps.20630.
- Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. J. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, A. Feilding, et al. 2016. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry 3 (7):619–27. doi:https://doi.org/10.1016/S2215-0366(16)30065-7.
- Chandler, J., and D. Shapiro. 2016. Conducting clinical research using crowdsourced convenience samples. Annual Review of Clinical Psychology 12. doi:https://doi.org/10.1146/annurev-clinpsy-021815-093623.
- Cipriani, A., T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson, Y. Ogawa, S. Leucht, H. G. Ruhe, E. H. Turner, J. P. Higgins, et al. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Focus 16 (4):420–29. doi:https://doi.org/10.1176/appi.focus.16407.
- Cohen, M., C. Beard, and T. Björgvinsson. 2015. Examining patient characteristics as predictors of patient beliefs about treatment credibility and expectancies for treatment outcome. Journal of Psychotherapy Integration 25 (2):90. doi:https://doi.org/10.1037/a0038878.
- Collins, A. B., S. B. Rutter, and A. Feder. 2020. Development of ketamine administration as a treatment for chronic PTSD. Psychiatric Annals 50 (2):68–76. doi:https://doi.org/10.3928/00485713-20200109-01.
- Constantino, M. J., A. E. Coyne, J. F. Boswell, B. R. Iles, and A. Vîslă. 2018. A meta-analysis of the association between patients’ early perception of treatment credibility and their posttreatment outcomes. Psychotherapy 55 (4):486. doi:https://doi.org/10.1037/pst0000168.
- Constantino, M. J., S. Penek, S. L. Bernecker, and C. E. Overtree. 2014. A preliminary examination of participant characteristics in relation to patients’ treatment beliefs in psychotherapy in a training clinic. Journal of Psychotherapy Integration 24 (3):238. doi:https://doi.org/10.1037/a0031424.
- Corriger, A., and G. Pickering. 2019. Ketamine and depression: A narrative review. Drug Design, Development and Therapy 13:3051. doi:https://doi.org/10.2147/DDDT.S221437.
- Cuijpers, P. 2017. Four decades of outcome research on psychotherapies for adult depression: An overview of a series of meta-analyses. Canadian Psychology/Psychologie Canadienn 58 (1):7–19. doi:https://doi.org/10.1037/cap0000096.
- Davies, J., and J. Read. 2019. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors 97:111–21. doi:https://doi.org/10.1016/j.addbeh.2018.08.027.
- Devilly, G. J., and T. D. Borkovec. 2000. Psychometric properties of the credibility/expectancy questionnaire. Journal of Behavior Therapy and Experimental Psychiatry 31 (2):73–86. doi:https://doi.org/10.1016/S0005-7916(00)00012-4.
- Dore, J., B. Turnipseed, S. Dwyer, A. Turnipseed, J. Andries, G. Ascani, C. Monnette, A. Huidekoper, N. Strauss, and P. Wolfson. 2019. Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs 51 (2):189–98. doi:https://doi.org/10.1080/02791072.2019.1587556.
- Earleywine, M., and J. De Leo. 2020. Psychedelic-assisted psychotherapy for depression. Journal of Psychedelic Studies 4 (2):88–92.
- Eaton, W. W., H. Shao, G. Nestadt, B. H. Lee, O. J. Bienvenu, and P. Zandi. 2008. Population-based study of first onset and chronicity in major depressive disorder. Archives of General Psychiatry 65:513–20. doi:https://doi.org/10.1001/archpsyc.65.5.513.
- Glue, P., S. Neehoff, A. Sabadel, L. Broughton, M. Le Nedelec, S. Shadli, N. McNaughton, and N. J. Medlicott. 2020. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology 34 (3):267–72. doi:https://doi.org/10.1177/0269881119874457.
- Graham, J. W., A. E. Olchowski, and T. D. Gilreath. 2007. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prevention Science 8 (3):206–13. doi:https://doi.org/10.1007/s11121-007-0070-9.
- Greenberg, P. E., A. A. Fournier, T. Sisitsky, C. T. Pike, and R. C. Kessler. 2015. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of Clinical Psychiatry 76 (2):155–62. doi:https://doi.org/10.4088/JCP.14m09298.
- Hasin, D. S., A. L. Sarvet, J. L. Meyers, T. D. Saha, J. Ruan, M. Stohl, and B. F. Grant. 2018. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75 (4):336–46. doi:https://doi.org/10.1001/jamapsychiatry.2017.4602.
- Hasler, G. 2020. Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectrums 25 (3):445–47. doi:https://doi.org/10.1017/S1092852919001007.
- Huang, E. C. H., C. Pu, Y. J. C, and N. Huang. 2018. Public trust in physicians– Health care commodification as a possible deteriorating factor: Cross-sectional analysis of 23 countries. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 55. https://doi.org/https://doi.org/10.1177/0046958018759174
- Ionescu, D. F., J. F. Rosenbaum, and J. E. Alpert. 2015. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in Clinical Neuroscience 17 (2):111.
- Irwin, S. A., A. Iglewicz, R. A. Nelesen, J. Y. Lo, C. H. Carr, S. D. Romero, and L. S. Lloyd. 2013. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. Journal of Palliative Medicine 16 (8):958–65. doi:https://doi.org/10.1089/jpm.2012.0617.
- Kemper, N. S., D. S. Campbell, M. Earleywine, and A. K. Newheiser. 2019. Likert, slider, or text? Reassurances about response format effects. Addiction Research & Theory 28 (5):1–9.
- Konttinen, H., F. Kilpi, H. Moustgaard, and P. Martikainen. 2016. Socioeconomic position and antidepressant use as predictors of coronary heart disease mortality: A population-based registry study of 362,271 Finns. Psychosomatic Medicine 78 (2):144–52. doi:https://doi.org/10.1097/PSY.0000000000000258.
- Li, L., and P. E. Vlisides. 2016. Ketamine: 50 years of modulating the mind. Frontiers in Human Neuroscience 10:612. doi:https://doi.org/10.3389/fnhum.2016.00612.
- Lin, J., H. Szukis, J. J. Sheehan, L. Alphs, B. Menges, M. Lingohr–Smith, and C. Benson. 2019. Economic burden of treatment–resistant depression among patients hospitalized for major depressive disorder in the United States. Psychiatric Research and Clinical Practice 1 (2):68–76. doi:https://doi.org/10.1176/appi.prcp.20190001.
- Liu, Q., H. He, J. Yang, X. Feng, F. Zhao, and J. Lyu. 2020. Changes in the global burden of depression from 1990 to 2017: Findings from the global burden of disease study. Journal of Psychiatric Research 126:134–40. doi:https://doi.org/10.1016/j.jpsychires.2019.08.002.
- Marcantoni, W. S., B. S. Akoumba, M. Wassef, J. Mayrand, H. Lai, S. Richard-Devantoy, and S. Beauchamp. 2020. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. Journal of Affective Disorders 277:831–41. doi:https://doi.org/10.1016/j.jad.2020.09.007.
- McCredie, M. N., and L. C. Morey. 2019. Who are the Turkers? A characterization of MTurk workers using the personality assessment inventory. Assessment 26 (5):759–66. doi:https://doi.org/10.1177/1073191118760709.
- McGirr, A., M. T. Berlim, D. J. Bond, M. P. Fleck, L. N. Yatham, and R. W. Lam. 2015. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 45 (4):693–704. doi:https://doi.org/10.1017/S0033291714001603.
- McIntyre, R. S., L. P. Carvalho, L. M. Lui, A. Majeed, P. S. Masand, H. Gill, N. B. Rodrigues, O. Lipsitz, A. C. Coles, Y. Lee, et al. 2020. The effect of intravenous, intranasal, and oral ketamine/esketamine in mood disorders: A meta-analysis. Journal of Affective Disorders 276:576–84. doi:https://doi.org/10.1016/j.jad.2020.06.050.
- Meade, A. W., and S. B. Craig. 2012. Identifying carless responding in survey data. Psychological Methods 17(3):437–455. https://doi.org/https://doi.org/10.1037/a0028085
- Newport, D. J., L. L. Carpenter, W. M. McDonald, J. B. Potash, M. Tohen, and C. B. Nemeroff; APA Council of Research Task Force on Novel Biomarkers and Treatments. 2015. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. American Journal of Psychiatry 172 (10):950–66. doi:https://doi.org/10.1176/appi.ajp.2015.15040465.
- Ophir, Y., I. Sisso, C. S. Asterhan, R. Tikochinski, and R. Reichart. 2020. The turker blues: Hidden factors behind increased depression rates among Amazon’s mechanical Turkers. Clinical Psychological Science 8 (1):65–83. doi:https://doi.org/10.1177/2167702619865973.
- Ophir, Y., and N. Mor. 2014. If I only knew why: The relationship between brooding, beliefs about rumination, and perceptions of treatments. Behavior Therapy 45 (4):553–63. doi:https://doi.org/10.1016/j.beth.2014.03.004.
- Palhano-Fontes, F., D. Barreto, H. Onias, K. C. Andrade, M. M. Novaes, J. A. Pessoa, S. A. Mota-Rolim, F. L. Osório, R. Sanches, R. G. Dos Santos, et al. 2019. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine 49 (4):655–63. doi:https://doi.org/10.1017/S0033291718001356.
- Peltoniemi, M. A., N. M. Hagelberg, K. T. Olkkola, and T. I. Saari. 2016. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clinical Pharmacokinetics 55 (9):1059–77. doi:https://doi.org/10.1007/s40262-016-0383-6.
- Read, J., and J. Williams. 2018. Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects. Current Drug Safety 13 (3):176–86. doi:https://doi.org/10.2174/1574886313666180605095130.
- Rush, A. J., M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg, M. E. Thase, and K. Shores-Wilson. 2006. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354 (12):1231–42. doi:https://doi.org/10.1056/NEJMoa052963.
- Sanacora, G., M. A. Frye, W. McDonald, S. J. Mathew, M. S. Turner, A. F. Schatzberg, P. Summergrad, and C. B. Nemeroff. 2017. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74 (4):399–405. doi:https://doi.org/10.1001/jamapsychiatry.2017.0080.
- Short, B., J. Fong, V. Galvez, W. Shelker, and C. K. Loo. 2018. Side-effects associated with ketamine use in depression: A systematic review. The Lancet Psychiatry 5 (1):65–78. doi:https://doi.org/10.1016/S2215-0366(17)30272-9.
- Talbot, J., J. L. Phillips, and P. Blier. 2019. Ketamine for chronic depression: Two cautionary tales. Journal of Psychiatry & Neuroscience: JPN 44 (6):384. doi:https://doi.org/10.1503/jpn.190073.
- Bureau U.S. Bureau of Labor Statistics. 2020. “CPI inflation calculator“. Accessed. April 11, 2021.https://www.bls.gov/data/inflation_calculator.htm.
- Van Buuren, S. 2018. Flexible imputation of missing data. CRC/Champan & Hall, Fl: Boca Raton.
- Vermetten, E., and R. Yehuda. 2020. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. Neuropsychopharmacology 45:231–32. doi:https://doi.org/10.1038/s41386-019-0482-9.
- Walter, M., S. Li, and L. R. Demenescu. 2014. Multistage drug effects of ketamine in the treatment of major depression. European Archives of Psychiatry and Clinical Neuroscience 264 (1):55–65. doi:https://doi.org/10.1007/s00406-014-0535-3.
- Walters, K., D. A. Christakis, D. R. Wright, and A. Alamian. 2018. Are mechanical Turk worker samples representative of health status and health behaviors in the US? PloS One 13 (6):e0198835. doi:https://doi.org/10.1371/journal.pone.0198835.
- World Health Organization [WHO]. 2017. Depression fact sheet. http://www.who.int/mediacentre/factsheets/fs369/en/
- Xu, Y., M. Hackett, G. Carter, C. Loo, V. Gálvez, N. Glozier, P. Glue, K. Lapidus, A. McGirr, A. A. Somogyi, et al. 2016. Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology 19 (4):1–15. doi:https://doi.org/10.1093/ijnp/pyv124.
- Zheng, W., X. H. Li, X. M. Zhu, D. B. Cai, X. H. Yang, G. S. Ungvari, and G. Wang. 2019. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. Journal of Affective Disorders 250:123–31. doi:https://doi.org/10.1016/j.jad.2019.02.044.
- Zimmermann, M., and A. Papa. 2020. Causal explanations of depression and treatment credibility in adults with untreated depression: Examining attribution theory. Psychology and Psychotherapy: Theory, Research and Practice 93 (3):537–54. doi:https://doi.org/10.1111/papt.12247.